# Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

> **NCT05626569** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Oligometastatic Disease

## Interventions

- **DRUG:** PD-1 combined with SBRT

## Key facts

- **NCT ID:** NCT05626569
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-10
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626569, "Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05626569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*